New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 at high risk. Abrysvo remains the only RSV vaccine approved for pregnant individuals to protect infants. Abrysvo now offers the ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

At the ITF Masters event in Bedford, NS, last month, the Canadians cleaned up by winning almost every title at the Atlantic ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals ...

NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...

The MONeT study enrolled individuals who had chronic pulmonary, cardiovascular, renal, hepatic, neurologic, hematologic or metabolic disorders. The Food and Drug Administration (FDA) has approved ...

Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant ...